(Q43040351)

English

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

scientific article published on 7 September 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Angela S Camacho

11

object named as

Angela Camacho

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Almudena Torres-Cornejo

6

object named as

Almudena Torres-Cornejo

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Josefa Ruiz-Morales

3

object named as

Josefa Ruiz-Morales

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ignacio de Los Santos-Gil

8

object named as

Ignacio de Los Santos-Gil

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mercedes González-Serrano

10

object named as

Mercedes González-Serrano

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

José A Mira

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Antonio Rivero

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Antonio Collado

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dolores Merino

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ginés Parra-García

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

7 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2605-2614

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Drug-induced liver injury associated with HIV medications

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR357

21 January 2018

Identifiers

10.1093/JAC/DKR357

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43040351&oldid=1978316323"